Literature DB >> 20660192

Vector choice determines immunogenicity and potency of genetic vaccines against Angola Marburg virus in nonhuman primates.

Thomas W Geisbert1, Michael Bailey, Joan B Geisbert, Clement Asiedu, Mario Roederer, Maria Grazia-Pau, Jerome Custers, Peter Jahrling, Jaap Goudsmit, Richard Koup, Nancy J Sullivan.   

Abstract

The immunogenicity and durability of genetic vaccines are influenced by the composition of gene inserts and choice of delivery vector. DNA vectors are a promising vaccine approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral vectors, but they have shown limited comparative efficacy as a stand-alone platform in primates, due possibly to suboptimal gene expression or cell targeting. Here, regimens using DNA plasmids modified for optimal antigen expression and recombinant adenovirus (rAd) vectors, all encoding the glycoprotein (GP) gene from Angola Marburg virus (MARV), were compared for their ability to provide immune protection against lethal MARV Angola infection. Heterologous DNA-GP/rAd5-GP prime-boost and single-modality rAd5-GP, as well as the DNA-GP-only vaccine, prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola. The DNA/DNA vaccine induced humoral responses comparable to those induced by a single inoculation with rAd5-GP, as well as CD4(+) and CD8(+) cellular immune responses, with skewing toward CD4(+) T-cell activity against MARV GP. Vaccine regimens containing rAd-GP, alone or as a boost, exhibited cellular responses with CD8(+) T-cell dominance. Across vaccine groups, CD8(+) T-cell subset dominance comprising cells exhibiting a tumor necrosis factor alpha (TNF-alpha) and gamma interferon (IFN-gamma) double-positive functional phenotype was associated with an absence or low frequency of clinical symptoms, suggesting that both the magnitude and functional phenotype of CD8(+) T cells may determine vaccine efficacy against infection by MARV Angola.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20660192      PMCID: PMC2937810          DOI: 10.1128/JVI.00594-10

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  Amine reactive dyes: an effective tool to discriminate live and dead cells in polychromatic flow cytometry.

Authors:  Stephen P Perfetto; Pratip K Chattopadhyay; Laurie Lamoreaux; Richard Nguyen; David Ambrozak; Richard A Koup; Mario Roederer
Journal:  J Immunol Methods       Date:  2006-05-19       Impact factor: 2.303

2.  Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major.

Authors:  Patricia A Darrah; Dipti T Patel; Paula M De Luca; Ross W B Lindsay; Dylan F Davey; Barbara J Flynn; Søren T Hoff; Peter Andersen; Steven G Reed; Sheldon L Morris; Mario Roederer; Robert A Seder
Journal:  Nat Med       Date:  2007-06-10       Impact factor: 53.440

Review 3.  T-cell quality in memory and protection: implications for vaccine design.

Authors:  Robert A Seder; Patricia A Darrah; Mario Roederer
Journal:  Nat Rev Immunol       Date:  2008-03-07       Impact factor: 53.106

Review 4.  DNA vaccines: ready for prime time?

Authors:  Michele A Kutzler; David B Weiner
Journal:  Nat Rev Genet       Date:  2008-10       Impact factor: 53.242

5.  Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections.

Authors:  Dana L Swenson; Danher Wang; Min Luo; Kelly L Warfield; Jan Woraratanadharm; David H Holman; John Y Dong; William D Pratt
Journal:  Clin Vaccine Immunol       Date:  2008-01-23

6.  Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses.

Authors:  Dana L Swenson; Kelly L Warfield; Tom Larsen; D Anthony Alves; Sadie S Coberley; Sina Bavari
Journal:  Expert Rev Vaccines       Date:  2008-05       Impact factor: 5.217

Review 7.  Current progress of DNA vaccine studies in humans.

Authors:  Shan Lu; Shixia Wang; Jill M Grimes-Serrano
Journal:  Expert Rev Vaccines       Date:  2008-03       Impact factor: 5.217

8.  Acquisition of direct antiviral effector functions by CMV-specific CD4+ T lymphocytes with cellular maturation.

Authors:  Joseph P Casazza; Michael R Betts; David A Price; Melissa L Precopio; Laura E Ruff; Jason M Brenchley; Brenna J Hill; Mario Roederer; Daniel C Douek; Richard A Koup
Journal:  J Exp Med       Date:  2006-12-11       Impact factor: 14.307

9.  Marburg virus Angola infection of rhesus macaques: pathogenesis and treatment with recombinant nematode anticoagulant protein c2.

Authors:  Thomas W Geisbert; Kathleen M Daddario-DiCaprio; Joan B Geisbert; Howard A Young; Pierre Formenty; Elizabeth A Fritz; Tom Larsen; Lisa E Hensley
Journal:  J Infect Dis       Date:  2007-11-15       Impact factor: 5.226

Review 10.  Correlates of protective immunity for Ebola vaccines: implications for regulatory approval by the animal rule.

Authors:  Nancy J Sullivan; Julie E Martin; Barney S Graham; Gary J Nabel
Journal:  Nat Rev Microbiol       Date:  2009-05       Impact factor: 60.633

View more
  35 in total

Review 1.  Filovirus vaccines.

Authors:  Steven B Bradfute; John M Dye; Sina Bavari
Journal:  Hum Vaccin       Date:  2011-06-01

2.  Clinical aspects of Marburg hemorrhagic fever.

Authors:  Masfique Mehedi; Allison Groseth; Heinz Feldmann; Hideki Ebihara
Journal:  Future Virol       Date:  2011-09       Impact factor: 1.831

Review 3.  Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Authors:  Jin Huk Choi; Maria A Croyle
Journal:  BioDrugs       Date:  2013-12       Impact factor: 5.807

4.  Antigen expression determines adenoviral vaccine potency independent of IFN and STING signaling.

Authors:  Kylie M Quinn; Daniel E Zak; Andreia Costa; Ayako Yamamoto; Kathrin Kastenmuller; Brenna J Hill; Geoffrey M Lynn; Patricia A Darrah; Ross W B Lindsay; Lingshu Wang; Cheng Cheng; Alfredo Nicosia; Antonella Folgori; Stefano Colloca; Riccardo Cortese; Emma Gostick; David A Price; Jason G D Gall; Mario Roederer; Alan Aderem; Robert A Seder
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

Review 5.  Recombinant vesicular stomatitis virus-based vaccines against Ebola and Marburg virus infections.

Authors:  Thomas W Geisbert; Heinz Feldmann
Journal:  J Infect Dis       Date:  2011-11       Impact factor: 5.226

6.  Chimpanzee adenovirus vaccine generates acute and durable protective immunity against ebolavirus challenge.

Authors:  Daphne A Stanley; Anna N Honko; Clement Asiedu; John C Trefry; Annie W Lau-Kilby; Joshua C Johnson; Lisa Hensley; Virginia Ammendola; Adele Abbate; Fabiana Grazioli; Kathryn E Foulds; Cheng Cheng; Lingshu Wang; Mitzi M Donaldson; Stefano Colloca; Antonella Folgori; Mario Roederer; Gary J Nabel; John Mascola; Alfredo Nicosia; Riccardo Cortese; Richard A Koup; Nancy J Sullivan
Journal:  Nat Med       Date:  2014-09-07       Impact factor: 53.440

Review 7.  A Comparison of the Pathogenesis of Marburg Virus Disease in Humans and Nonhuman Primates and Evaluation of the Suitability of These Animal Models for Predicting Clinical Efficacy under the 'Animal Rule'.

Authors:  Elizabeth R Glaze; Michael J Roy; Lonnie W Dalrymple; Lynda L Lanning
Journal:  Comp Med       Date:  2015-06       Impact factor: 0.982

Review 8.  Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.

Authors:  John J Suschak; Connie S Schmaljohn
Journal:  Hum Vaccin Immunother       Date:  2019-10-07       Impact factor: 3.452

Review 9.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

10.  Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Authors:  Devon J Shedlock; Jenna Aviles; Kendra T Talbott; Gary Wong; Stephan J Wu; Daniel O Villarreal; Devin Jf Myles; Maria A Croyle; Jian Yan; Gary P Kobinger; David B Weiner
Journal:  Mol Ther       Date:  2013-05-14       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.